Melanoma News and Research

Latest Melanoma News and Research

Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer

Plexxikon announced today the results of a Phase 1 extension study in metastatic colorectal cancer that showed clinical activity of PLX4032 as a single agent in this hard-to-treat patient population. PLX4032 is a novel, oral small molecule targeting an oncogenic BRAF mutation found in over 50 percent of melanomas, about 10 percent of colorectal cancers and eight percent of all solid tumors.

7 Jun 2010

Positive results from Phase 3 trial of ipilimumab in patients with metastatic melanoma

Bristol-Myers Squibb Company today announced positive results from a Phase 3 randomized, double blind study of ipilimumab which demonstrated that overall survival was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab.

7 Jun 2010

Phase III trial comparing PHP with melphalan to BAC for hepatic metastases highlighted at ASCO 2010

Delcath Systems, Inc. a development stage, specialty pharmaceutical and medical device company focused on oncology, highlighted the Phase III trial data presented on June 5 at the American Society of Clinical Oncology's 2010 Annual Meeting, comparing percutaneous hepatic perfusion with melphalan to the best alternative care for patients with hepatic metastases from ocular or cutaneous melanoma.

7 Jun 2010

NewLink Genetics reports positive data from Phase 2 trial of HyperAcute-Pancreas cancer immunotherapy

NewLink Genetics Corporation today announced positive Phase 2 clinical trial data of its HyperAcute®-Pancreas cancer immunotherapy combined with standard adjuvant chemotherapy in patients with surgically resectable pancreatic cancer. The study results suggest a potentially longer disease-free survival and one-year overall survival in this patient group than reported in previous studies of surgery and adjuvant therapy alone. These data were presented in a poster session at the American Society of Clinical Oncology (ASCO) annual meeting.

7 Jun 2010

Addition of sorafenib to chemotherapy regimen not effective against advanced melanoma: Study

The combination of two different chemotherapies and a previously approved treatment for kidney and liver cancers is not effective against advanced melanoma, according to results disclosed in an oral presentation today at the 46th annual meeting of the American Society of Clinical Oncology in Chicago.

7 Jun 2010

Celldex reports interim positive results from rindopepimut Phase 2b study for GBM at ASCO

Celldex Therapeutics, Inc. today announced that interim results from a Phase 2b study evaluating rindopepimut (formerly PF-04948568 or CDX-110) in newly-diagnosed glioblastoma multiforme (GBM) patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).

7 Jun 2010

bioTheranostics presents positive outcomes from CancerTYPE ID, Breast Cancer Index clinical studies

bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company's CancerTYPE ID® and Breast Cancer Index® molecular oncology tests. Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago.

7 Jun 2010

ZymoGenetics' IL-21 Phase 2 clinical trial in metastatic melanoma meets primary endpoint

ZymoGenetics, Inc. today announced positive results from a Phase 2 clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. The trial met the primary endpoint of efficacy, as measured by objective response rate or lack of early disease progression. Overall response rate was 23.1%, in evaluable patients, and median progression-free survival was 4.3 months. The results were presented at the American Society of Clinical Oncology meeting.

7 Jun 2010

Celldex Therapeutics reports mature data from CDX-011 Phase 1/2 study in advanced breast cancer

Celldex Therapeutics, Inc. today announced that mature results from a Phase 1/2 study evaluating CDX-011 in advanced stage breast cancer patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). CDX-011 is an experimental antibody-drug conjugate (ADC) directed against glycoprotein NMB (GPNMB) and linked to a potent cancer cell-killing drug, monomethyl-auristatin E (MMAE).

7 Jun 2010

COMMD1 protein restrains metastatic potential of invasive cancer cell line: Researchers

Researchers at UT Southwestern Medical Center have determined that cancer cells lacking a key protein are more invasive and more likely to metastasize, providing a possible drug target to combat certain tumor types.

5 Jun 2010

High IL-10 levels in tumor cells may decrease effectiveness of autologous melanoma vaccine: Study

Scientists from the Kimmel Cancer Center at Jefferson have found that interleukin-10 production in tumor cells is a possible prognostic factor in patients with advanced melanoma who are treated with autologous melanoma cell vaccine. They are presenting their data at the 2010 ASCO Annual Meeting in Chicago (Abstract #8588).

5 Jun 2010

PEB's European licensee SDX completes clinical trial for prognostic gene signature for colorectal cancer

Pacific Edge (PEB), a New Zealand-based biomedical company, today announced the successful completion of the European clinical trial for their prognostic gene signature for colorectal cancer. The clinical trial results showed a successful outcome that enables patients diagnosed with UICC stage II or UICC stage III colorectal cancer and with a high risk of disease progression to be identified and treated more appropriately.

5 Jun 2010

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.

4 Jun 2010

Scancell's ImmunoBody vaccine technologies to be combined with ImmuneRegen's Homspera

Scancell Holdings Plc, the developer of therapeutic cancer vaccines, today announces a strategic collaboration with ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc.. Under the agreement, Scancell and ImmuneRegen will work together to investigate the synergy between ImmuneRegen's Homspera® and Scancell's ImmunoBody® vaccine technologies.

4 Jun 2010

Study confirms Azilect as a selective MAO-B inhibitor

Teva Neuroscience Inc. today announced the publication of a study demonstrating the selectivity of Azilect® (rasagiline tablets) for inhibition of MAO-B (monoamine oxidase-B) at the maximum approved dose of 1 mg/day. The data was published in the Journal of Clinical Pharmacology OnlineFirst on May 5, 2010.

4 Jun 2010

NICE updates recommendations on diagnosis, treatment of low risk BCCs

The National Institute for Health and Clinical Excellence has updated its recommendations on the diagnosis and treatment of 'low risk' basal cell carcinomas.

3 Jun 2010

Top physicians offer health advice to help people survive during summer

This summer a variety of top physicians at NewYork-Presbyterian Hospital are offering health advice to help survive the travails that come with one of the most active seasons of the year.

3 Jun 2010

Incidence of skin cancer cases increases particularly among teenagers

With the family beach vacation right around the corner, keeping children's skin safe under the hot, summer sun should be top of mind for every parent. Recently, doctors at Nationwide Children's Hospital have seen an increase in the incidence of skin cancer cases among children ages 5-16-years-old, and particularly among teenagers. In fact, melanoma - cancer of the skin's pigment elements - is now responsible for approximately one out of 10 cancer cases in adolescents ages 15-19-years-old.

3 Jun 2010

ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C

ZymoGenetics, Inc. today announced the initiation of the second part of a Phase 2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection. ZymoGenetics is developing the investigational compound PEG-Interferon lambda in collaboration with Bristol-Myers Squibb Company.

2 Jun 2010

Study demonstrates diagnostic, economic benefits of AABT for lung cancer patients

Oncimmune LLC, maker of EarlyCDT-Lung, a simple blood test that aids physicians in risk assessment and the early detection of lung cancer, today announced validation study results demonstrating the diagnostic and economic benefits of a standardized and reproducible autoantibody laboratory test that may significantly improve the prognosis for lung cancer patients.

2 Jun 2010

Melanoma News and Research

Latest Melanoma News and Research

Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer

Positive results from Phase 3 trial of ipilimumab in patients with metastatic melanoma

Phase III trial comparing PHP with melphalan to BAC for hepatic metastases highlighted at ASCO 2010

NewLink Genetics reports positive data from Phase 2 trial of HyperAcute-Pancreas cancer immunotherapy

Addition of sorafenib to chemotherapy regimen not effective against advanced melanoma: Study

Celldex reports interim positive results from rindopepimut Phase 2b study for GBM at ASCO

bioTheranostics presents positive outcomes from CancerTYPE ID, Breast Cancer Index clinical studies

ZymoGenetics' IL-21 Phase 2 clinical trial in metastatic melanoma meets primary endpoint

Celldex Therapeutics reports mature data from CDX-011 Phase 1/2 study in advanced breast cancer

COMMD1 protein restrains metastatic potential of invasive cancer cell line: Researchers

High IL-10 levels in tumor cells may decrease effectiveness of autologous melanoma vaccine: Study

PEB's European licensee SDX completes clinical trial for prognostic gene signature for colorectal cancer

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Scancell's ImmunoBody vaccine technologies to be combined with ImmuneRegen's Homspera

Study confirms Azilect as a selective MAO-B inhibitor

NICE updates recommendations on diagnosis, treatment of low risk BCCs

Top physicians offer health advice to help people survive during summer

Incidence of skin cancer cases increases particularly among teenagers

ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C

Study demonstrates diagnostic, economic benefits of AABT for lung cancer patients

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Melanoma News and Research

Latest Melanoma News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in